Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPARgamma1 but not that for the adipocyte-specific gamma2 isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL). Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPARgamma mRNA level in HSC from BDL. Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-1 binding were increased. Treatment of cultured-activated HSC with ligands for PPARgamma (10 microm 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)); 0.1 approximately 10 microm BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2) was abrogated 70% by the concomitant treatment with a PPARgamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPARalpha and gamma (>100 microm) but not at those that only activate PPARalpha (<10 microm) or by a synthetic PPARalpha-selective agonist (GW9578). 15dPGJ(2) reduced alpha1(I) procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36. 15dPGJ(2) and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor alpha (10 ng/ml) reduced PPARgamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2). These results demonstrate that HSC activation is associated with the reductions in PPARgamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPARgamma ligands in vitro. These findings implicate diminished PPARgamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPARgamma ligands for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIG. 4 A , PPAR g (15dPGJ2, BRL49653) ligands inhibit HSC DNA and collagen synthesis. The 3-4-day primary cultures of HSC were exposed to 15dPGJ2 (1 and 10 m M), BRL49653 (1 and 10 m M), or WY14643 (10 ; 250 m M) for 18 h, and [ 3 H]thymidine incorporation into DNA was assessed. Note a significant, ; 40%, inhibition in HSC DNA synthesis by 15dPGJ2 and BRL49653 at 10 m M and WY14643 at 100 and 250 m M. *, p , 0.05; **, p , 0.01 compared with the respective control. DMSO , Me2SO. B , collagen production by cultured HSC, as determined by incorporation of [ 3 H]proline into collagenase-sensitive peptides was significantly inhibited by 18 h of treatment with 15dPGJ 2 (10 m M), BRL49653 (0.1 ; 10 m M), and WY14643 (100 m M). *, p , 0.05; **,](https://figures.cochat.ai/paper-figures/a66e36c4743842c5bde9349747bed49a/peroxisome-proliferator-activated-receptors-and-hepatic-stellate-cell-activation-figure-4.png)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist with anticholestatic, 14 anti-inflammatory, 15 and antifibrotic 16 properties”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationThomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 9
- Friedman, S. L., Wei, S., and Blaner, W. S. (1993) Am. J. Physiol. 264, G947-G952
- Tsukamoto, H., Cheng, S., and Blaner, W. S. (1996) Am. J. Physiol. 270, G581-G586
- Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
- Okuno, M., Moriwaki, H., Imai, S., Muto, Y., Kawada, N., Suzuki, Y., and Kojima, S. (1997) Hepatology 26, 913-921
- Potter, J. J., Womack, L., Mezey, E., and Anania, F. A. (1998) Biochem. Cell Biol.244, 178 -182
- Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., and Tsukamoto, H. (1997) Am. J. Physiol. 272, G1355-G1364
- Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251
- Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B. M., and Moller, D. E. (1996) Mol. Endocrinol. 10, 1457-1466
- Tsukamoto, H. (1999) Alcohol Clin. Exp. Res. 23, 911-916 · doi:10.1111/j.1530-0277.1999.tb04202.x · Paper page
Cited by
Items 201–300 of 477
Uto, H., Nakanishi, C., Ido, A., Hasuike, S., Kusumoto, K., Hirohiko, A. B. E., Numata, M., NAGATA, K., Hayashi, K., & Tsubouchi, H. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.05.008 · Cited by 57
Han, S., Inoue, H., Flowers, L., & Sidell, N. (2003) · PubMed · Cited by 52
The Role of PPARs in Breast Cancer
Zhao, B., Xin, Z., Ren, P., & Wu, H. (2022) · Cells · doi:10.3390/cells12010130 · Cited by 60
“The earliest PPARβ/δ antagonist used is an irreversible PPARγ antagonist, GW9662 [69].”
BackgroundInfluentialQian, J., Niu, M., Zhai, X., Zhou, Q., & Zhou, Y. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.06.003 · Cited by 51
The use of marine-derived bioactive compounds as potential hepatoprotective agents
Nair, D. G., Weiskirchen, R., & Al-Musharafi, S. K. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.114 · Cited by 56
Zhou, Y., Jia, X., Wang, G., Wang, X., & Liu, J. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0027-3 · Cited by 54
“As PPARc can reverse HSC activation and maintain HSC quiescence [16, 17, 19], it seems reasonable that the inhibitory effect of leptin on PPARc gene expression might contribute to HSC activation, thus promoting liver fibrosis.”
BackgroundSato-Matsubara, M., Matsubara, T., Daikoku, A., Okina, Y., Longato, L., Rombouts, K., Thuy, L. T. T., Adachi, J., Tomonaga, T., Ikeda, K., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793794 · Cited by 51
“We also examined the effect of supplement solution and FGF2 on the expression of PPAR , which is a master regulator of adipogenesis and is reported to be suppressed in cultured–activated human and rat HSCs (28, 29).”
BackgroundTsolaki, E., Athanasiou, E., Gounari, E., Ζώγας, Ν., Siotou, E., Yiangou, M., Anagnostopoulos, Α., & Yannaki, E. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.05.003 · Cited by 51
Transdifferentiation in developmental biology, disease, and in therapy
Thowfeequ, S., Myatt, E., & Tosh, D. (2007) · Developmental Dynamics · doi:10.1002/dvdy.21336 · Cited by 60
“Adipogenic transcription factors such as peroxisome proliferator-activated receptor- (PPAR ) and sterol regulatory element binding protein-1c (SRBP1c) maintain HSCs in a quiescent state (Miyahara et al., 2000; She et al., 2005).”
BackgroundChen, Q., Chen, L., Kong, D., Shao, J., Wu, L., & Zheng, S. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.011 · Cited by 52
Lakner, A. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i40.5047 · Cited by 49
Effects of PPARg agonist pioglitazone on rat hepatic fibrosis
Yuan, G., Zhang, M., & Gong, Z. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i7.1047 · Cited by 53
Peroxisome Proliferator Activated Receptors
Genolet, R., Michalik, L., & Wahli, W. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_22 · Cited by 49
Vassiliadis, E., Larsen, D. V., Clausen, R. E., Veidal, S. S., Barascuk, N., Larsen, L., Simonsen, H., Segovia‐Silvestre, T., Hansen, C., Overgaard, T., et al. (2011) · Biomarker Insights · doi:10.4137/bmi.s6347 · Cited by 48
Jiang, Y., Wang, S., Zhao, Y., Lin, C., Zhong, F., Jin, L., He, F., & Wang, H. (2015) · The FASEB Journal · doi:10.1096/fj.14-251751 · Cited by 48
“Transcriptional silencing of the PPARg gene is required for HSC myofibroblastic conversion; its exogenous overexpression in hepatic myofibroblasts results in reversionof transdifferentiation (7, 8).”
Backgroundvan der Veen, J. N., Lingrell, S., Gao, X., Quiroga, A. D., Takawale, A. R., Armstrong, E. A., Yager, J. Y., Kassiri, Z., Lehner, R. S., Vance, D. E., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2015 · Cited by 55
“PPAR is expressed in hepatic stellate cells, and its expression and transcriptional activity are strikingly reduced during the process of activation from the quiescent phenotype to a highly proliferative and fibrotic phenotype (17, 31, 32, 63).”
BackgroundTuohetahuntila, M., Spee, B., Kruitwagen, H. S., Wubbolts, R., Brouwers, J. F. H. M., van de Lest, C. H. A., Molenaar, M. R., Houweling, M., Helms, J. B., & Vaandrager, A. B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.003 · Cited by 54
Amplified Inhibition of Stellate Cell Activation Pathways by PPAR-γ, RAR and RXR Agonists
Sharvit, E., Abramovitch, S., Reif, S., & Bruck, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076541 · Cited by 44
“In addition, PPARγ can bind to the RARE as a PPARγ-RXR heterodimer and regulated its expression in lung and breast cancer cell line [19].”
BackgroundSugiyama, A., Kanno, K., Nishimichi, N., Ohta, S., Ono, J., Conway, S. J., Izuhara, K., Yokosaki, Y., & Tazuma, S. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1206-0 · Cited by 51
Liu, Q., Wang, C. Y., Liu, Z., ́s, X. B., He, Y., Chen, S. S., & Bai, X. (2014) · Pharmaceutical Biology · doi:10.3109/13880209.2013.877491 · Cited by 46
“…factor superfamily and is involved in the activation and apoptosis of HSCs. Previous studies have demonstrated that the level of PPAR-g was high in quiescent HSCs, but that its expression and activity were reduced during HSC activation in vitro and in vivo (Miyahara et al., 2000; She et al., 2005).”
BackgroundResolving fibrosis in the diseased liver: Translating the scientific promise to the clinic
Muddu, A. K., Guha, I. N., Elsharkawy, A. M., & Mann, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.10.006 · Cited by 57
Fatty acid regulation of gene expression
Grimaldi, P. A. (2001) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200109000-00015 · Cited by 46
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Tang, Y. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3487-6 · Cited by 46
“Accumulating evidence supports the proposal that recovering the accumulation of lipids could inhibit HSC activation [68, 69].”
BackgroundInfluentialVitamin A and lipid metabolism: relationship between hepatic stellate cells (HSCs) and adipocytes
Sauvant, P., Cansell, M., & Atgié, C. (2011) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-011-0101-7 · Cited by 47
“The transcription factor, PPAR-γ has been proposed as a potential molecular target for inhibition of HSC transdifferentiation [40].”
BackgroundResultNanomedicines of Hedgehog Inhibitor and PPAR-γ Agonist for Treating Liver Fibrosis
Kumar, V., Mundra, V., & Mahato, R. I. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1239-5 · Cited by 48
Qiao, H., Han, H., Hong, D., Ren, Z., Chen, Y., & Zhou, C. (2010) · Pharmaceutical Biology · doi:10.3109/13880209.2010.493179 · Cited by 45
“, 2000), Stimulation of PPARγ activity by its potential agonists could inhibit HSC proliferation and α1(I) collagen expression (Miyahara et al., 2000), which were all confirmed by our study.”
BackgroundResultInfluentialHo, T., Chen, S., Shih, S., Wu, J.-Y., Han, W.-H., Cheng, H.-C., Yang, S.-L., & Tsao, Y. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091085 · Cited by 45
“To seek in vivo evidence of PEDF on NF- B, we investigated, by double immunostaining for p65 (a NF- B subunit) and HSC marker -SMA, whether AAVPEDF treatment is able to block CCl4–induced NF- B nuclear translocation in hepatic HSCs.”
BackgroundInfluentialShimizu, K., Shiratori, K., Kobayashi, M., & Kawamata, H. (2004) · Pancreas · doi:10.1097/00006676-200407000-00058 · Cited by 50
“These characteristic features of PSCs are similar to those of hepatic stellate cells (HSCs), which play an important role in the pathogenesis of liver fibrosis, and a recent study reported that PPAR ligand inhibits the platelet-derived growth factor (PDGF)–stimulated proliferation and production of ECM by HSCs.(18,19)…”
BackgroundInfluentialThe role of curcumin in liver diseases
Buonomo, A. R., Scotto, R., Nappa, S., Arcopinto, M., Salzano, A., Marra, A. M., D’Assante, R., Zappulo, E., Borgia, G., & Gentile, I. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.73596 · Cited by 47
“Furthermore, another crucial mechanism involved in liver fibrosis is the reduction of PPARc expression in HSCs: in fact, PPARc is highly expressed in inactive HSCs, while its activity is reduced when HSCs are activated both in vivo and in vitro [65, 75, 76].”
BackgroundTargeting 15d-Prostaglandin J2 to Hepatic Stellate Cells: Two Options Evaluated
Hagens, W. I., Mattos, A., Greupink, R., de Jager-Krikken, A., Reker-Smit, C., van Loenen-Weemaes, A., Gouw, A. S. H., Poelstra, K., & Beljaars, L. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9175-2 · Cited by 44
“In addition, sub-apoptotic concentrations of 15dPGJ2 significantly inhibited the expression of interstitial collagens as well as its proliferation in human hepatic myofibroblasts in vitro (17,18).”
BackgroundRole of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
Lee, S. M., Muratalla, J. T., Sierra‐Cruz, M., & Córdoba‐Chacón, J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0155 · Cited by 49
Reversal of liver fibrosis in aryl hydrocarbon receptor null mice by dietary vitamin A depletion
Andreola, F., Calvisi, D. F., Elizondo, G., Jakowlew, S. B., Mariano, J. M., Gonzalez, F. J., & Luca, L. M. D. (2004) · Hepatology · doi:10.1002/hep.20004 · Cited by 53
Lee, J., Asai, M., Jeon, S.-K., Iimura, T., Yonezawa, T., Cha, B., Woo, J., & Yamaguchi, A. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400164 · Cited by 43
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Xiao, Y., Kim, M., & Lazar, M. A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101119 · Cited by 43
“PPARg ligand treatment in activated stellate cells or a liver fibrotic mouse model can reduce collagen gene expression both in vitro and in vivo, but the mechanism of how PPARg functions on chromatin to suppress gene expression is not completely understood [117,118].”
BackgroundIL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells
Mathurin, P., Xiong, S., Kharbanda, K. K., Veal, N., Miyahara, T., Motomura, K., Rippe, R. A., Bachem, M. G., & Tsukamoto, H. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2001 · Cited by 42
“HSC isolated from the BDL model have previously been characterized to be activated and to have increased expression of procollagen1(I), transforming growth factor- 1, and -smooth muscle actin (24, 26).”
BackgroundSelf-citationHepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
Silibinin Inhibits Proliferation and Migration of Human Hepatic Stellate LX-2 Cells
Ezhilarasan, D., Evraerts, J., Sid, B., Calderón, P. B., Karthikeyan, S., Sokal, E. M., & Najimi, M. (2016) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2016.01.002 · Cited by 44
“Furthermore, studies have shown that PPAR-g activity is expressed highly in quiescent HSCs of normal liver and its activity are reduced in activated rat and human HSCs, which undergo proliferation.(12,13) Additionally, it has been shown that the treatment of culture activated HSCs with PPAR-g ligands reversed the coll…”
BackgroundInfluentialLee, J. H., Jang, J. K., Ko, K. Y., Jin, Y., Ham, M., Kang, H., & Kim, I. Y. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0180-x · Cited by 41
New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article
Ebrahimi, H., Naderian, M., & Sohrabpour, A. A. (2018) · Middle East Journal of Digestive Diseases · doi:10.15171/mejdd.2018.103 · Cited by 41
Genesis of hepatic fibrosis and its biochemical markers
Das, S. K., & Vasudevan, D. M. (2008) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510701668516 · Cited by 45
“The peroxisome proliferators activated receptor, isoform gamma (PPAR gamma), is also shown to be involved in the molecular regulation of HSC activation [16].”
BackgroundTsukamoto, H. (2005) · The Keio Journal of Medicine · doi:10.2302/kjm.54.190 · Cited by 42
Self-citationZhou, Q., Guan, W., Qiao, H., Cheng, Y., Li, Z., Zhai, X., & Zhou, Y. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.001 · Cited by 47
Acetaldehyde Inhibits PPARγ via H2O2-Mediated c-Abl Activation in Human Hepatic Stellate Cells
Ceni, E., Crabb, D. W., Foschi, M., Mello, T., Tarocchi, M., Patussi, V., Moraldi, L., Moretti, R., Milani, S., Surrenti, C., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.009 · Cited by 42
Zhao, Z., Fan, Y., Zhao, Q., Dou, C., Ji, X., Zhao, J., Gao, S., Li, X., & Wang, K. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0149-2 · Cited by 38
“PPAR-γ was believed to be involved in hepatic stellate cells (HSCs) activation and differentiation which was a core event in liver fibrosis and was a pivotal gene to maintain the adipogenic phenotype characteristics of HSCs and prevent the initiation of fibrosis [31].”
BackgroundNew Therapies for Primary Biliary Cirrhosis
Floreani, A., Franceschet, I., Perini, L., Cazzagon, N., Gershwin, M. E., & Bowlus, C. L. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8456-5 · Cited by 38
“the reduction of PPARγ expression in vivo and is reversed by the treatment with PPARγ ligands in vitro, indicating a potential anti-fibrotic role of this nuclear receptor [49].”
BackgroundRey, J. W., Noetel, A., Hardt, A., Canbay, A., Alakus, H., Hausen, A. Z., Dienes, H.-P., Drebber, U., & Odenthal, M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i46.5830 · Cited by 42
Antihepatic Fibrosis Drugs in Clinical Trials
Guo, Y., & Lu, L. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00023 · Cited by 44
“As distinct PPAR isoforms, PPARa regulates cholesterol and bile acid homeostasis,(28) while PPARg contributes to inhibiting the activation of HSCs and reducing collagen production.(29) Hence, PPAR is a potential target for hepatic fibrosis.”
BackgroundWound Healing in the Biliary Tree of Liver Allografts
Demetris, A. J., Fontes, P., Lunz, J. G., Specht, S. M., Murase, N., & Marcos, A. (2006) · Cell Transplantation · doi:10.3727/000000006783982386 · Cited by 40
Ameliorative effect of curcumin on hepatotoxicity induced by chloroquine phosphate
Dattani, J. J., Rajput, D. K., Moid, N., Highland, H. N., George, L.-B., & Desai, K. R. (2010) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2010.04.001 · Cited by 40
“In addition, HSC activation oincides with a dramatic reduction in expression of the PPAR- (Galli et al., 2000; Marra et al., 2000; Miyahara et al., 2000).”
BackgroundZhang, G.-Y., Yi, C.-G., Li, X., Ma, B., Li, Z.-J., Chen, X.-L., Guo, S.-Z., & Gao, W.-Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08989.x · Cited by 41
Poleni, P.-E., Bianchi, A., Etienne, S., Koufany, M., Sébillaud, S., Netter, P., Terlain, B. L., & Jouzeau, J. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.10.009 · Cited by 44
Peroxisome Proliferator‐Activated Receptor and Retinoic X Receptor in Alcoholic Liver Disease
Mello, T., Polvani, S., & Galli, A. (2009) · PPAR Research · doi:10.1155/2009/748174 · Cited by 42
“[52] T.”
Morphogens and hepatic stellate cell fate regulation in chronic liver disease
Tsukamoto, H., Zhu, N., Wang, J., Asahina, K., & Machida, K. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07022.x · Cited by 37
Self-citationLin, X., Zhang, S., Huang, Q., Wei, L., Li, Z., Chen, Z., Jiao, Y., Huang, J., Fu, S., & Huang, R. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.05.040 · Cited by 38
Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats
Bassiouny, A. R., Zaky, A., Fawky, F., & Kandeel, K. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31521-2 · Cited by 39
Ohata, M., Suzuki, H., Sakamoto, K., Hashimoto, K., Nakajima, H., Yamauchi, M., Hokkyo, K., Yamada, H., & Toda, G. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000134412.38510.f7 · Cited by 38
Crabb, D. W., Pinairs, J., Hasanadka, R., Fang, M. M., Leo, M. A., Lieber, C. S., Tsukamoto, H., Motomura, K., Miyahara, T., Ohata, M., et al. (2001) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02398.x · Cited by 38
Self-citationFibrate treatment for primary biliary cirrhosis
Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000056 · Cited by 36
“PPARg, finally, did not directly interfere with bile acid metabolism, but repressed the transactivation of inflammatory response genes, and had antifibrotic effects on hepatic stellate cells [71].”
BackgroundTsai, T., Shih, S., Ho, T., Ma, H., Liu, M., Chen, S., & Tsao, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095443 · Cited by 36
“PPARc is highly expressed in quiescent HSCs in the normal liver and its expression decreases dramatically in activated HSCs both in vitro [21,22] and in vivo [22,23].”
BackgroundLv, X., Fang, C., Yin, R., Qiao, B., Shang, R., Wang, J., Song, W., He, Y., & Chen, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.22186 · Cited by 36
Fat paradox of steatohepatitis
Tsukamoto, H., She, H., Hazra, S., Cheng, J. H., & Wang, J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05294.x · Cited by 38
Self-citationOldenburg, A. R., Delbarre, E., Thiede, B., Vigouroux, C., & Collas, P. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt509 · Cited by 36
“Interestingly, lipofibroblasts of mesodermal origin exist in several organs (66–68), and their adipogenic phenotype can be altered to that of myofibroblasts under pathological conditions (66,67).”
BackgroundDocosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats
He, J., Bai, K., Hong, B., Zhang, F., & Zheng, S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.09.013 · Cited by 38
Feng, Z., Xiang, J., Liu, H., Li, J., Xu, X., Sun, G., Zheng, R., Zhang, S., Liu, J., Yang, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02002 · Cited by 36
Involvement of C/EBP-α gene in in vitro activation of rat hepatic stellate cells
Huang, G., Zhang, J.-S., & Tang, Q.-Q. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.196 · Cited by 35
Targeted delivery of drugs for liver fibrosis
Li, F., & Wang, J. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902936834 · Cited by 38
“15d-Prostaglandin J2 (15dPGJ2) induced apoptosis of human hepatic myofibroblasts and significantly inhibited the expression of interstitial collagens as well as their proliferation in human hepatic myofibroblasts in vitro [66-68]; but prostaglandins are locally acting mediators that are rapidly metabolized, resulting…”
BackgroundPitavastatin inhibits hepatic steatosis and fibrosis in non‐alcoholic steatohepatitis model rats
Miyaki, T., Nojiri, S., Shinkai, N., Kusakabe, A., Matsuura, K., Iio, E., Takahashi, S., Yan, G., Ikeda, K., & Joh, T. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00769.x · Cited by 38
Hepatic stellate cell line modulates lipogenic transcription factors
Guimarães, E. L. M., Franceschi, M. F. S., Andrade, C. M. B., Guaragna, R. M. V. D. C., Borojević, R., Margis, R., Bernard, E. A., & Guma, F. T. C. R. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01578.x · Cited by 39
“The discovery that PPARg expression is modulated during HSC activation suggests that its ligands exert antifibrotic effects and highlights a possible involvement of this transcription factor in liver fibrosis (32) The ectopic expressions of PPARg and C/EBPa were enough to restore several markers of the quiescent pheno…”
BackgroundEpigenetic Modifications in Hepatic Stellate Cells Contribute to Liver Fibrosis
Zhao, Q., Qin, C., Zhao, Z., Fan, Y., & Wang, K. (2012) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.229.35 · Cited by 38
“In this process, suppression of PPAR-γ expression was demonstrated to be regulated in complicated epigenetic ways, which influences the secretion of chemokines and proteins from HSCs (Miyahara et al. 2000).”
BackgroundInfluentialNrf2 activation is required for curcumin to induce lipocyte phenotype in hepatic stellate cells
Lu, C., Xu, W., & Zheng, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.037 · Cited by 35
Mermelstein, C., Guma, F. T. C. R., Mello, T. G., Fortuna, V., Guaragna, R. M. V. D. C., Costa, M. L., & Borojević, R. (2001) · Cell and Tissue Research · doi:10.1007/s004410100428 · Cited by 34
Pasqua, L. G. D., Cagna, M., Berardo, C., Vairetti, M., & Ferrigno, A. (2022) · Biomedicines · doi:10.3390/biomedicines10010194 · Cited by 37
“The administration of PPARγ agonist 15dPGJ2 in cultured activated HSC reduced collagen synthesis, whereas the co-administration of PPARγ agonist 15dPGJ2 with the PPARγ antagonist GW9662 abrogated 70% of the collagen reduction obtained by the agonist alone, showing the potential therapeutic effect of PPARγ ligands in t…”
BackgroundLee, K.-W., Thiyagarajan, V., Sie, H.-W., Cheng, M.-F., Tsai, M., Chia, Y., & Weng, C.-F. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.04.001 · Cited by 32
“During HSCs activation, the abundance and trans-activating activity of PPAR-γ are substantially diminished and lose lipid droplets storage in contrast to PPAR-γ, which is highly expressed in quiescent HSCs [32,33].”
Backgroundthe Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, R., de Vries, E. S., Parés, A., Helder, J., Kemper, E. M., Zwinderman, K., Elferink, R. P. O., & Beuers, U. (2017) · Trials · doi:10.1186/s13063-017-1966-8 · Cited by 31
“As an agonist of peroxisome proliferator-activated receptors (PPARs), bezafibrate has anti-inflammatory [36–38], anticholestatic [20, 39–42] and antifibrotic [43] properties.”
BackgroundRamani, K., Donoyan, S., Tomasi, M. L., & Park, S. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24839 · Cited by 31
“HSC activation is associated with induction of protein markers such as alpha-smooth muscle actin (a-SMA), Type I collagen, myocyte enhancer factor 2A (MEF2A), and loss of quiescenceassociated factors such as peroxisome-proliferator activated receptor g (PPARg) (Miyahara et al., 2000).”
BackgroundZhang, G., Cheng, T., Zheng, M., Yi, C., Pan, H., Li, Z., Chen, X., Yu, Q., Jiang, L., Zhou, F.-Y., et al. (2009) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2009.06.032 · Cited by 36
Gonzalez‐Sanchez, E., Firrincieli, D., Housset, C., & Chignard, N. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.04.004 · Cited by 33
Δ9-Tetrahydrocannabinolic Acid markedly alleviates liver fibrosis and inflammation in mice
Carmona‐Hidalgo, B., González‐Mariscal, I., García‐Martín, A., Prados, M. E., Ruíz-Pino, F., Appendino, G., Tena‐Sempere, M., & Muñóz, E. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153426 · Cited by 33
Zhang, J., Powell, C. A., Kay, M., Sonkar, R., Meruvu, S., & Choudhury, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041822 · Cited by 35
“As evidenced before, hepatic expression of PPARγ is increased in people with NAFL [46] while decreased during liver fibrogenesis in NASH [47,48].”
BackgroundInfluentialRau, O., Syha, Y., Zettl, H., Kock, M., Bock, A., & Schubert‐Zsilavecz, M. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200700209 · Cited by 36
Simón, E., Macarulla, M. T., Churruca, I., Fernández‐Quintela, A., & Portillo, M. P. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.06.001 · Cited by 36
“Primers used for PPARg were those designed previously [18].”
MethodLu, C., Xu, W., Shao, J., Zhang, F., Chen, A., & Zheng, S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.06.001 · Cited by 34
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
Bennett, R. G., Simpson, R. L., & Hamel, F. G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i22.3999 · Cited by 31
Bian, E., Zhao, B., Huang, C. Z., Wang, H., Meng, X., Wu, B., Ma, T., Zhang, L., Lv, X., & Li, J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.017 · Cited by 34
Morais, A. D. S., Abarca‐Quinones, J., Horsmans, Y., Stärkel, P., & Leclercq, I. A. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.1.105 · Cited by 32
“PPAR Á has been shown to be expressed in quiescent HSCs and its expression and activity decreased during HSC activation in vitro and in vivo in rats (6,7,9).”
Peroxisome proliferator activated receptor-γ in pathogenesis of experimental fatty liver disease
Zhao, C., Jiang, L., Li, L., Deng, Z., Liang, B.-L., & Li, J. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i9.1329 · Cited by 32
Rosa, A. O., Egea, J., Martínez, A., García, A. G., & López, M. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.03.008 · Cited by 31
“Since NP00111 and rosiglitazone were protective but the GSK-3β inhibitors lithium and AR-A014418 failed to afford protection against OGD, we decided to evaluate if the protective effects of NP00111 and rosiglitazone could be blocked by the PPARγ antagonist GW9662 (Miyahara et al., 2000).”
BackgroundCapsaicin up-regulates pro-apoptotic activity of thiazolidinediones in glioblastoma cell line
Szoka, Ł., & Palka, J. A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110741 · Cited by 30
Pro-inflammatory properties for thiazolidinediones
Desmet, C. J., Warzée, B., Gosset, P., Melotte, D., Rongvaux, A., Gillet, L., Fiévez, L., Seumois, G., Vanderplasschen, A. F. C., Staels, B., et al. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.09.017 · Cited by 32
Curcumin adds spice to the debate: lipid metabolism in liver disease
Graham, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00335.x · Cited by 28
“This paradox was highlighted by Tsukamoto et al. (Miyahara et al., 2000; Hazra et al., 2004; Tsukamoto, 2005; Tsukamoto et al., 2006), who observed that trans-differentiation of HSC to MF essentially models adipocytes-pre-adipocytic fibroblast de-differentiation: both quiescent HSC and adipocytes…”
BackgroundInfluentialZhou, J., Liu, X., Chen, T., Cheng, G., & Cai, S. (2020) · Food & Function · doi:10.1039/d0fo00548g · Cited by 27
Carson, J. P., Robinson, M. W., Ramm, G. A., & Gobert, G. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06774-3 · Cited by 32
Xing, X., Chen, S., Li, L., Cao, Y., Chen, L., Wang, X., & Zhu, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00525 · Cited by 29
“The level of PPARG was higher in quiescent HSCs, compared to activated HSCs; and its abundance, expression, and transcriptional activity were all suppressed during HSCs activation in vivo and in vitro (Galli et al., 2000; Miyahara et al., 2000; She et al., 2005).”
BackgroundHuang, Q. F., Zhang, S. J., Zheng, L., Liao, M., He, M., Huang, R., Zhuo, L., & Lin, X. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.03.044 · Cited by 30
“…weight was related to the toxicity of the ethanol because ethanol impaired the activation and utilization of nutrients due to maldigestion or malabsorption (Lieber, 2000), while increased liver weight could be due to accumulation of lipids and collagen (Galli et al., 2000; Miyahara et al., 2000).”
BackgroundZhi, S., Chen, S., Li, Y., Li, J., Zheng, Y., & Yu, F. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5462-8 · Cited by 27
RetractedZhu, X., Jia, X., Cheng, F., Tian, H., & Zhou, Y. (2020) · The Journal of Pathology · doi:10.1002/path.5536 · Cited by 30
Amirinejad, A., Totmaj, A. S., Mardali, F., Hekmatdoost, A., Emamat, H., Safa, M., & Shidfar, F. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03396-x · Cited by 28
Wang, Q., Hou, G., Yin, Y., Han, D., & Kang, J. (2015) · International Journal of COPD · doi:10.2147/copd.s77514 · Cited by 27
“18 Recently, PPAR γ agonists have begun to be used as an anti-inflammatory therapy for COPD.”
Bruck, R., Weiss, S., Aeed, H., Pines, M., Halpern, Z., & Zvibel, I. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0336-5 · Cited by 25
“PPARc ligands reduce both basal collagen I production and TGFb1-induced collagen I mRNA expression in cultured activated HSC [13].”
Background
Metadata
- Authors
- Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Maryland, College Park (US)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 46
- Pages
- 35715-35722
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2025657436
- Cited by
- 473
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 17 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7274 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs
- University of Southern California (DK48522)
- National Institutes of Health (5k08dk002450-05, AA10459)
- National Institute on Alcohol Abuse and Alcoholism (AA10459, R37AA006603, R37-AA-06603, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-02450)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- peroxisome proliferator-activated receptors, PPARγ, hepatic stellate cell activation, liver fibrosis, cholestatic liver fibrosis, bile duct ligation, PPAR ligands, collagen synthesis, PPAR-responsive element, TNF-α, matrix metalloproteinase-3
- MeSH terms
- Rosiglitazone, Animals, Cell Survival, Cells, Cultured, Collagen, DNA, Gene Expression Regulation, Liver, Liver Cirrhosis, Biliary, Liver Cirrhosis, Experimental, Male, Promoter Regions, Genetic, Protein Binding, Pyrimidines, RNA, Messenger, Thiazoles, Transcription Factors, Tumor Necrosis Factor-alpha, Prostaglandin D2, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Protein Isoforms, Thiazolidinediones, Cell Size, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.